Price movement over the last 24 hours
Amgen, Inc. vs Monolithic Power Systems Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Monolithic Power Systems Inc trades at $1,316.5 (market cap $66.46B). The key difference: Amgen, Inc. is far larger — about 3× Monolithic Power Systems Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MPWR | |
|---|---|---|
Market Cap | $196.12B | $66.46B |
Sector | Health | Utilities |
52-Week High | $388.16 | $1.69K |
52-Week Low | $271.18 | $711.24 |
Enterprise Value | $241.41B | $65.11B |
Dividend Yield | 2.77% | 0.59% |
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MPWR trades at $1,352.74, down 1.56% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company demonstrates strong profitability with a 22.98% net income margin and consistent earnings beats in recent quarters. Analyst sentiment is overwhelmingly positive with 88% buy ratings and a consensus price target of $1,760. Recent news highlights ongoing investigations into corporate governance alongside positive coverage of AI infrastructure growth opportunities.
The outlook for MPWR remains favorable given its earnings momentum and positioning in AI and power management semiconductors. Key opportunities include expanding demand in data centers and telecom, while risks involve high valuation multiples and corporate governance scrutiny. The stock offers growth potential but requires monitoring of execution against elevated expectations.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →